Geneva, Oct. 15 -- International Clinical Trials Registry received information related to the study (ChiCTR2600133996) titled 'Effectiveness and Safety of Crisugabalin Besylate for Migraine Prophylaxis: A RealWorld Observational Cohort Study' on Oct. 10.
Study Type: Observational study
Study Design:
Cohort study
Primary Sponsor: Beijing Tiantan Hospital, Capital Medical University
Condition:
migraine
Recruitment Status: Not Recruiting
Phase: 4
Date of First Enrollment: 2026-10-10
Target Sample Size: Crisugabalin Besilate Capsules:500;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj=346758
Published by HT Digital Content Services with permission from Health Daily Digest....